Dialysis Co. Pays $7.3M To Settle FCA Overbilling Claims
Dialysis company U.S. Renal Care agreed to pay $7.3 million to settle whistleblower allegations that a Maryland subsidiary violated the False Claims Act by excessively charging Medicare for the anemia drug...To view the full article, register now.
Already a subscriber? Click here to view full article